# Efficacy and Safety of Immunotherapy With Allogeneic Dendritic Cells, DCP-001, in Patients With Acute Myeloid Leukaemia

> **NCT03697707** · PHASE2 · UNKNOWN · sponsor: **Mendus** · enrollment: 20 (estimated)

## Conditions studied

- Acute Myeloid Leukemia in Remission

## Interventions

- **BIOLOGICAL:** DCP-001

## Key facts

- **NCT ID:** NCT03697707
- **Lead sponsor:** Mendus
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-10-15
- **Primary completion:** 2023-03
- **Final completion:** 2025-12
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2022-10-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03697707

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03697707, "Efficacy and Safety of Immunotherapy With Allogeneic Dendritic Cells, DCP-001, in Patients With Acute Myeloid Leukaemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03697707. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*